Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Even in healthy aging, cardiac morbidity and mortality increase with age in both mice and humans. These effects include a decline in diastolic function, left ventricular hypertrophy, metabolic substrate shifts, and alterations in the cardiac proteome. Previous work from our laboratory indicated that short‐term (10‐week) treatment with rapamycin, an mTORC1 inhibitor, improved measures of these age‐related changes. In this report, we demonstrate that the rapamycin‐dependent improvement of diastolic function is highly persistent, while decreases in both cardiac hypertrophy and passive stiffness are substantially persistent 8 weeks after cessation of an 8‐week treatment of rapamycin in both male and female 22‐ to 24‐month‐old C57BL/6NIA mice. The proteomic and metabolomic abundance changes that occur after 8 weeks of rapamycin treatment have varying persistence after 8 further weeks without the drug. However, rapamycin did lead to a persistent increase in abundance of electron transport chain (ETC) complex components, most of which belonged to Complex I. Although ETC protein abundance and Complex I activity were each differentially affected in males and females, the ratio of Complex I activity to Complex I protein abundance was equally and persistently reduced after rapamycin treatment in both sexes. Thus, rapamycin treatment in the aged mice persistently improved diastolic function and myocardial stiffness, persistently altered the cardiac proteome in the absence of persistent metabolic changes, and led to persistent alterations in mitochondrial respiratory chain activity. These observations suggest that an optimal translational regimen for rapamycin therapy that promotes enhancement of healthspan may involve intermittent short‐term treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 1×
“Rapamycin extends murine lifespan in both sexes, even when administered at 9 or 20 months of age in genetically heterogeneous mice (Harrison et al., 2009; Miller et al., 2011), and in C57BL/6 mice at 19 (Zhang et al., 2014) or 20–21 months of age (Bitto et al., 2016).”
BackgroundThe pathophysiology of heart failure with preserved ejection fraction
Borlaug, B. A. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.83 · Cited by 726 · cited 1×
“Diastolic dysfunction limits cardiac reserve, which can lead to symptoms of exercise intolerance, and ultimately muscle wasting, loss of independence, and pulmonary venous congestion (Borlaug, 2014).”
BackgroundTransient rapamycin treatment can increase lifespan and healthspan in middle-aged mice
Bitto, A., Ito, T. K., Pineda, V. V., LeTexier, N. J., Huang, H. Z., Sutlief, E., Tung, H., Vizzini, N., Chen, B., Smith, K., et al. (2016) · eLife · doi:10.7554/elife.16351 · Cited by 474
Adverse events associated with mTOR inhibitors
Pallet, N., & Legendre, C. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.752814 · Cited by 198
Rapamycin transiently induces mitochondrial remodeling to reprogram energy metabolism in old hearts
Chiao, Y. A., Kolwicz, S. C., Basisty, N., Gagnidze, A., Zhang, J., Gu, H., Djukovic, D., Beyer, R. P., Raftery, D., MacCoss, M., et al. (2016) · Aging · doi:10.18632/aging.100881 · Cited by 128 · cited 5×
“While the metabolomic profile change that is evident within the first few weeks of rapamycin treatment (Chiao et al., 2016) may be important for diastolic functional improvement, it does not appear to be necessary for the persistent benefits.”
BackgroundMethodSelf-citationRapamycin-induced metabolic defects are reversible in both lean and obese mice
Liu, Y., Diaz, V., Fernandez, E., Strong, R., Ye, L., Baur, J. A., Lamming, D. W., Richardson, A., & Salmon, A. B. (2014) · Aging · doi:10.18632/aging.100688 · Cited by 68 · cited 1×
“Other studies have indicated that rapamycin's effects on glucose metabolism and insulin regulation are also phasic and reversible (Blum, 2002; Liu et al., 2014).”
Background
Cited by
Epigenetic regulation of aging: implications for interventions of aging and diseases
Wang, K., Liu, H., Hu, Q., Wang, L., Liu, J., Zheng, Z., Zhang, W., Ren, J., Zhu, F., & Liu, G.-H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01211-8 · Cited by 663
Inflammation, Aging, and Cardiovascular Disease
Liberale, L., Badimon, L., Montecucco, F., Lüscher, T. F., Libby, P., & Camici, G. G. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.017 · Cited by 462
Effect of rapamycin on aging and age-related diseases—past and future
Selvarani, R., Mohammed, S., & Richardson, A. (2021) · GeroScience · doi:10.1007/s11357-020-00274-1 · Cited by 290
Hallmarks of cardiovascular ageing
Abdellatif, M., Rainer, P. P., Sedej, S., & Kroemer, G. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00881-3 · Cited by 274
Roadmap for alleviating the manifestations of ageing in the cardiovascular system
Liberale, L., Tual-Chalot, S., Sedej, S., Ministrini, S., Georgiopoulos, G., Grunewald, M., Bäck, M., Bochaton-Piallat, M.-L., Boon, R. A., Ramos, G. C., et al. (2025) · Nature Reviews Cardiology · doi:10.1038/s41569-025-01130-5 · Cited by 59
“Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR) that is approved by the FDA for rejection prophylaxis after organ transplantation, delayed ageing-related cardiac systolic and diastolic function in mice 309,310 and dogs 311 .”
Metadata
- Authors
- Quarles, E., Basisty, N., Chiao, Y. A., Merrihew, G., Gu, H., Sweetwyne, M. T., Fredrickson, J., Nguyen, N., Razumova, M., Kooiker, K., Moussavi‐Harami, F., Regnier, M., Quarles, C., MacCoss, M., & Rabinovitch, P. S.
- Venue
- Aging Cell
- Publisher
- Wiley
- Published
- 2019-12-10
- Volume
- 19
- Issue
- 2
- Pages
- e13086-e13086
- ISSN
- 1474-9718 (ISSN-L)
- 1474-9726
- OpenAlex
- W2996589793
- Cited by
- 102
- References
- 6
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment. https://app.cochat.ai/papers/10.1111/acel.13086
- The paper
- Quarles, E., Basisty, N., Chiao, Y. A., Merrihew, G., Gu, H., Sweetwyne, M. T., Fredrickson, J., Nguyen, N., Razumova, M., Kooiker, K., Moussavi‐Harami, F., Regnier, M., Quarles, C., MacCoss, M., & Rabinovitch, P. S. (2020). Rapamycin persistently improves cardiac function in aged, male and female mice, even following cessation of treatment. Aging Cell. https://doi.org/10.1111/acel.13086
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.